Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Slides:

Advertisements

Similar presentations

Prognostic significance of DDB2 in ovarian cancer.

Advertisements

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Tumor development of poorly immunogenic LLC and B16F10 cells modified to produce GM-CSF was markedly inhibited. Tumor development of poorly immunogenic.

Depletion of T cells, in particular CD8+ T cells, significantly abrogates HEV neogenesis in tumors. Depletion of T cells, in particular CD8+ T cells, significantly.

Potential mechanisms of therapeutic synergy between epigenetic modulation and PD-1 pathway blockade. Potential mechanisms of therapeutic synergy between.

B7-H4 expression correlates with MHC-I expression and improved prognosis in patients with breast cancer. B7-H4 expression correlates with MHC-I expression.

Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.

IL32 prompts cell activation and cancer-related pathways.

Quantification of MHC-I, β2m, and T-cell subsets.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

Exosome-mediated inhibition of T cells is reversible.

Gene expression changes associated with response to combination CPI-444 and anti–PD-L1 treatment in MC38 tumors. Gene expression changes associated with.

L-ICON1 is effective for the treatment of murine TNBC (4T1/Luc + GFP) in an orthotopic CDX model. L-ICON1 is effective for the treatment of murine TNBC.

Frequency and kinetics of killer cell apoptosis are dependent on functional conjugations with multiple NALM-6 tumor cells. Frequency and kinetics of killer.

Geographic colocalization of PD-L1+ tumor cells with infiltrating immune cells in MCC. The predominant pattern of tumor cell PD-L1 expression is at the.

IL32 is highly expressed in mycosis fungoides lesional skin.

Treatment with R848 and anti-CD200R leads to changes in the composition of intratumor myeloid cells. Treatment with R848 and anti-CD200R leads to changes.

coTCRcys-transduced T cells control tumor growth in vivo.

Antitumor activity of KM100+5 μmol/L MTX treatment in the presence or absence of CD8+ T cells in BALB-neuT mice bearing subcutaneous tumors of TUBO cells.

Protein expression profile in a dasatinib-resistant cell line.

CXCL14-positive CAFs induce overexpression of LINC00092 in ovarian cancer. CXCL14-positive CAFs induce overexpression of LINC00092 in ovarian cancer. A,

IL6 mRNA is not detected in metastatic prostate cancer cells.

CD94/NKG2A+ TILs lack tissue resident CD103 marker.

Heat map of genes for which CR significantly altered expression versus AL. Cluster analysis of genes significantly changed by the CR intervention compared.

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

Presentations of thyroid disorders after receiving immune checkpoint inhibition combination therapy or monotherapy. Presentations of thyroid disorders.

Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.

Experimental metastasis inhibition by primary tumors is mediated by NK cells and IFNγ. Experimental metastasis inhibition by primary tumors is mediated.

Time to onset of hypothyroidism after first treatment with immune checkpoint inhibitors in the combination therapy and monotherapy groups. Time to onset.

Positive correlations between disease course and treatment-induced immune responses. Positive correlations between disease course and treatment-induced.

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

EN1 expression in breast cancer and clinical outcome.

Induction of a tumor-specific immune response following radiofrequency ablation (RFA). Induction of a tumor-specific immune response following radiofrequency.

ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells, and NK cells. ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells,

Epithelial-derived cancer cells and tumor-residing APCs have higher HLA-E expression but reduced MHC-1a expression. Epithelial-derived cancer cells and.

Dual blockade of PD-1 and CTLA-4 directly activates CD4+Foxp3− cells in the absence of CD8+ or CD4+Foxp3+ cells. Dual blockade of PD-1 and CTLA-4 directly.

Irradiated whole-cell vaccination with MOC1, but not MOC2, induces immunologic memory. Irradiated whole-cell vaccination with MOC1, but not MOC2, induces.

Mir-128 reduction in breast cancer tissues correlates chemotherapy resistance and poor patient survival. Mir-128 reduction in breast cancer tissues correlates.

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

Intratumoral lymphoid aggregates are sites of postvaccination T-cell activation and regulation. Intratumoral lymphoid aggregates are sites of postvaccination.

Influenza vaccine enhances NK cell function through IFN-α.

Extraction diagram of candidate genes identified by global expression analysis. Extraction diagram of candidate genes identified by global expression analysis.

PD-L1 is expressed in breast cancer.

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Influence of ASGR2 expression on survival.

Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

CPI-444 enhances T-cell activation in MC38 tumors.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.

Monocytes from melanoma patients are unresponsive to TLR3 agonists.

CTLA-4 and PD-1 modulate different aspects of the T-cell response: A, CTLA-4 is upregulated after antigen-specific activation of a naïve or memory T cell.

The influence of diverse genotypes of rs on the expression of MAVS (A), IFNβ (B), in PBMCs of healthy individuals. The influence of diverse genotypes.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

Nanostring analysis of tumors after ILI and after combination limb infusion and ipilimumab. Nanostring analysis of tumors after ILI and after combination.

TNFα-expanded MRD cells acquire the recurrence-competent phenotype.

In situ expression of signature genes in the Th1, Th2, Th17, and Treg pathways. In situ expression of signature genes in the Th1, Th2, Th17, and Treg pathways.

CPI-444 synergizes with anti–PD-L1 and anti–CTLA-4 treatment.

Cell counts of immune infiltrate and expression of galectin-1 and galectin-3 in the short-, medium-, and long-term survival cohorts. Cell counts of immune.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

Low initial levels of CD4+ Tregs, proliferating CD8+, and Granzyme B+ CD8+ T cells and high posttreatment tumor MHC class II expression predict better.

Overexpression of SUFU and GLI1 in the poor clinical outcome subgroup was confirmed by real-time PCR along with its association with disease progression.

Waterfall plots in 82 ipilimumab-refractory patients receiving nivolumab (3 mg/kg) with (n = 14) or without (n = 82) a peptide vaccine. Waterfall plots.

GSN and DNMT1 expression are inversely correlated in a pattern associated with patient survival. GSN and DNMT1 expression are inversely correlated in a.

Presentation transcript:

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Clinical details of patient 1 (not including immunologic studies) were reported previously (30). After IFNβ monotherapy, patient 1 subsequently experienced 8+ years of disease-free survival. Three patients who received intralesional IFN injections as part of their MCC treatment who had specimens available from before and after IFN treatment are shown. A significant increase in MHC-I expression was observed on tumor cells after treatment (P = 0.04; paired t test). Kelly G. Paulson et al. Cancer Immunol Res 2014;2:1071-1079 ©2014 by American Association for Cancer Research